the effect of the addition of pegvisomant on quality of life and glucose sensitivity in acromegaly patients

Registry ID

EUCTR2011-004231-31

Source registry

EUCTR

Status

Ongoing

Phase

PHASE3

Sponsor

Erasmus University Medical Centre Rotterdam

Start date

2011-10-18

Last update

2026-08-16

Conditions

• acromegaly

Summary

To assess the efficacy and safety of the co-administration of low-dose pegvisomant (40 mg, administered via subcutaneous injection given once a week) and long-acting somatostatin analogs (administered once monthly) on the Quality of Life over 16 weeks in 60 acromegalic patients

Locations

• , , Netherlands

View on source registry